Zynex Inc

Healthcare US ZYXI

2.25USD
-0.18(7.41%)

Last update at 2025-03-28T20:00:00Z

Day Range

2.232.43

LowHigh

52 Week Range

6.8813.77

LowHigh

Fundamentals

Previous Close 2.43
Market Cap321.25M
Volume255559
P/E Ratio43.96
Dividend Yield-%
EBITDA15.64M
Revenue TTM188.68M
Revenue Per Share TTM5.47
Gross Profit TTM 126.52M
Diluted EPS TTM0.23

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Analyst Recommendations

Deadline Alert: Zynex, Inc. (ZYXI) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Fri 28 Mar 25, 04:51 PM
DEADLINE ALERT for TBBK, ZYXI, PPTA, and UCTT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Fri 28 Mar 25, 04:11 PM
Investors in Zynex, Inc. Should Contact Levi & Korsinsky Before May 19, 2025 to Discuss Your Rights – ZYXI
Thu 27 Mar 25, 05:04 PM
Wolf Haldenstein informs investors that Zynex, Inc. has been sued
Wed 26 Mar 25, 09:14 PM
Faruqi & Faruqi Reminds Zynex Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 19, 2025 – ZYXI
Wed 26 Mar 25, 08:18 PM
Zynex, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – ZYXI
Wed 26 Mar 25, 02:59 PM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zynex, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZYXI
Wed 26 Mar 25, 12:00 PM
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZYXI
Tue 25 Mar 25, 09:00 PM
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Zynex, Inc. (ZYXI) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Tue 25 Mar 25, 05:05 PM
ZYNEX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Zynex, Inc. and Encourages Investors to Contact the Firm
Tue 25 Mar 25, 01:00 AM

Financials

Income Statement

Total Revenue

Net Income

Balancesheet

Total Assets

Total Liabilities

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Income before tax	22.20M	22.27M	10.15M	11.94M	10.22M
Minority interest	-	-	-	-0.08900M	-0.08900M
Net income	17.05M	17.10M	9.07M	9.49M	9.55M
Selling general administrative	36.11M	26.32M	18.32M	11.58M	15.51M
Selling and marketing expenses	67.12M	54.29M	34.13M	14.02M	-
Gross profit	126.16M	102.98M	62.70M	36.66M	25.88M
Reconciled depreciation	3.13M	2.29M	1.57M	0.78M	0.45M
Ebit	19.81M	20.08M	10.25M	10.29M	9.92M
Ebitda	22.94M	22.37M	11.74M	11.07M	10.37M
Depreciation and amortization	3.13M	2.29M	1.50M	0.78M	0.45M
Non operating income net other	-0.30000M	-	-0.07700M	0.88M	-
Operating income	22.94M	22.37M	10.25M	11.07M	10.37M
Other operating expenses	135.23M	107.94M	69.87M	34.41M	21.55M
Interest expense	0.44M	0.10M	0.02M	0.00500M	0.15M
Tax provision	5.15M	5.17M	1.08M	2.45M	0.66M
Interest income	-	-	-	0.00500M	0.15M
Net interest income	-0.44000M	-0.09500M	-0.01900M	-0.00500M	-0.15400M
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	5.15M	5.17M	1.08M	2.45M	0.66M
Total revenue	158.17M	130.30M	80.12M	45.47M	31.92M
Total operating expenses	103.22M	80.61M	52.46M	25.59M	15.51M
Cost of revenue	32.01M	27.32M	17.42M	8.81M	6.04M
Total other income expense net	-0.74000M	-0.09500M	-0.09600M	0.88M	-0.15400M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	17.05M	17.10M	9.07M	9.49M	9.55M
Net income applicable to common shares	17.05M	17.10M	9.07M	9.49M	9.55M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Total assets	141.07M	116.47M	133.27M	72.17M	28.28M
Intangible assets	8.16M	9.07M	9.97M	-	-
Earning assets	-	-	-	-	-
Other current assets	3.33M	0.87M	0.69M	1.38M	0.32M
Total liab	94.94M	50.11M	59.35M	15.32M	8.62M
Total stockholder equity	46.13M	66.36M	73.92M	56.85M	19.74M
Deferred long term liab	-	-	-	-	-
Other current liab	5.54M	5.99M	9.82M	3.27M	1.81M
Common stock	0.03M	0.04M	0.04M	0.04M	0.03M
Capital stock	0.03M	0.04M	0.04M	0.04M	0.03M
Retained earnings	26.78M	17.05M	0.00000M	23.43M	14.36M
Other liab	-	10.00M	9.70M	-	-
Good will	20.40M	20.40M	20.40M	-	-
Other assets	0.00000M	2.15M	1.30M	0.91M	0.84M
Cash	44.58M	20.14M	42.61M	39.17M	14.04M
Cash and equivalents	-	-	-	-	-
Total current liabilities	18.53M	21.09M	22.87M	10.12M	5.20M
Current deferred revenue	0.63M	1.56M	-	-	-
Net debt	31.59M	6.82M	-7.52400M	-31.84200M	-9.35700M
Short term debt	3.92M	7.94M	8.31M	2.13M	1.26M
Short long term debt	-	5.33M	5.33M	-	-
Short long term debt total	76.17M	26.96M	35.09M	7.33M	4.68M
Other stockholder equity	19.32M	49.27M	73.88M	33.39M	5.35M
Property plant equipment	-	2.17M	18.91M	1.93M	4.87M
Total current assets	87.86M	69.56M	82.69M	63.02M	22.57M
Long term investments	-	-	-	-	-
Net tangible assets	-	36.89M	43.55M	56.85M	19.74M
Short term investments	-	-	-	-	-
Net receivables	26.84M	35.06M	28.63M	13.84M	5.83M
Long term debt	57.60M	5.29M	10.61M	-	-
Inventory	13.11M	13.48M	10.76M	8.63M	2.38M
Accounts payable	8.43M	5.60M	4.74M	4.72M	2.13M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-0.08900M
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	0.00000M	-	-	-	-2.06300M
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	0.04M	0.04M	0.04M	0.03M
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	17.05M	-	23.43M	14.36M
Treasury stock	-	-	-6.51300M	-3.84600M	-3.84600M
Accumulated amortization	-	-	-	-	-
Non currrent assets other	-7.74900M	0.86M	0.97M	0.67M	0.51M
Deferred long term asset charges	-	-	-	-	-
Non current assets total	53.22M	46.91M	50.59M	9.15M	5.71M
Capital lease obligations	18.56M	16.33M	19.15M	7.33M	4.68M
Long term debt total	-	5.29M	10.61M	-	0.14M

Breakdown	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Investments	-0.41800M	-16.60600M	-0.98500M	-0.16000M	-1.08200M
Change to liabilities	1.83M	2.89M	3.77M	0.79M	0.35M
Total cashflows from investing activities	-0.41800M	-16.60600M	-0.98500M	-0.16000M	-1.08200M
Net borrowings	-5.33300M	15.95M	-0.05700M	-0.01900M	-0.50700M
Total cash from financing activities	-35.79600M	13.10M	25.30M	-2.23100M	-3.76300M
Change to operating activities	-0.18600M	0.45M	-0.66500M	0.31M	0.06M
Net income	17.05M	17.10M	9.07M	9.49M	9.55M
Change in cash	-22.46800M	3.44M	25.13M	3.91M	4.56M
Begin period cash flow	42.61M	39.17M	14.04M	10.13M	5.57M
End period cash flow	20.14M	42.61M	39.17M	14.04M	10.13M
Total cash from operating activities	13.75M	6.95M	0.82M	6.30M	9.41M
Issuance of capital stock	-	0.00000M	25.20M	0.22M	0.18M
Depreciation	3.13M	2.29M	1.57M	0.78M	0.45M
Other cashflows from investing activities	-	-15.99700M	-	-	-
Dividends paid	3.61M	0.00100M	0.00100M	2.26M	2.27M
Change to inventory	-4.32000M	-3.77600M	-7.32300M	-2.36000M	-0.41400M
Change to account receivables	-6.43000M	-14.78100M	-8.00400M	-3.04200M	-0.60600M
Sale purchase of stock	-26.42600M	-2.66700M	25.77M	-0.17100M	-3.43200M
Other cashflows from financing activities	-0.35200M	-0.25200M	0.15M	-0.16000M	-1.08200M
Change to netincome	1.79M	1.48M	2.63M	1.22M	-0.35200M
Capital expenditures	0.42M	0.61M	0.98M	0.16M	1.08M
Change receivables	-6.43000M	-14.78100M	-8.00400M	-3.04200M	-0.60600M
Cash flows other operating	0.70M	1.74M	-0.90100M	-0.56700M	0.27M
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-22.46800M	3.44M	25.13M	3.91M	4.56M
Change in working capital	-9.10200M	-15.21500M	-12.21900M	-4.30400M	-0.60700M
Stock based compensation	2.34M	1.63M	2.68M	0.82M	0.37M
Other non cash items	1.18M	1.29M	-0.23600M	-0.69500M	0.37M
Free cash flow	13.33M	6.34M	-0.16700M	6.14M	8.33M

Peer Comparison

Sector: Healthcare Industry: Medical Distribution

Company	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
ZYXI Zynex Inc	-0.18 7.41%	2.25	43.96	23.81	2.06	8.24	2.23	23.00
MCK McKesson Corporation	2.39 0.36%	668.06	17.95	14.53	0.20	5.04	0.22	12.17
COR Cencora Inc.	1.24 0.45%	275.21	23.39	-	-	-
CAH Cardinal Health Inc	-0.21 0.15%	136.44	166.11	14.71	0.12	16.07	0.12	19.78
HSIC Henry Schein Inc	-0.78 1.12%	68.62	24.12	14.04	0.74	2.50	0.95	13.33

Reports Covered

View All

Profile

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

Zynex Inc

9655 Maroon Circle, Englewood, CO, United States, 80112

303 703 4906
https://www.zynex.com
Employees : 1100

Key Executives

Name	Title	Year Born
Mr. Thomas Sandgaard	Founder, Pres, CEO & Chairman	1959
Mr. Daniel J. Moorhead	Chief Financial Officer	1972
Ms. Anna Lucsok	Chief Operating Officer	1986
Ms. Chelle Van Burkleo	VP of Sales	NA
Mr. Steve Fox	VP Of Sales	NA
Mr. Dave Anttila	Director of HR	NA
Mr. Neil Friery	Pres & COO of Zynex Monitoring Solutions, Inc.	NA
Mr. Joachim Sandgaard	Information Systems Mang.	NA
Mr. Donald Gregg	VP of Sales and Operations - Monitoring Solutions Division	NA
Mr. Thomas Sandgaard	Founder, President, CEO & Chairman	1959

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.